Stanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. This is part 3 of a 3-part series, where we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We conclude the series with Carolyn Rodriguez.Carolyn Rodriguez is Associate Dean at Stanford University School of Medicine and a psychiatrist at the Palo Alto VA. As Director of the Rodriguez Translational Therapeutics Lab, she leads studies on severe mental illness. Her clinical trials pioneer rapid-acting treatments for OCD and related disorders demonstrating ketamine's efficacy in reducing OCD symptoms. She now plans placebo-controlled studies of MDMA and other psychedelics, unlocking their therapeutic potential for OCD.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis,  Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Boris Heifets, an assistant professor at Stanford's School of Medicine, discusses his research on the effects of ketamine on patients with depression under anesthesia. He also explores the impact of different environments on the effects of psilocybin in mice and reflects on the hype cycle of psychedelics.

Psychedelics have long been known to induce altered states of consciousness. But there are many other techniques that can also expand our awareness - from meditation and breathwork to exploring dreams, prayer, light and sound. In this episode, Greg speaks with Scott Britton about the emerging startup landscape around tools for expanding consciousness.Scott is an entrepreneur who now writes a newsletter called Consciousness ∞ The Doorway to Human Evolution He also hosts a podcast called EvolutionFM.This special episode is a deeper dive into Greg & Scott’s recent article about the consciousness startup ecosystem.In this episode, we discuss:VC-backable business models in psychedelic medicineHardware devices that induce deeper meditation and lucid dream statesBreathwork: app vs. in-person experiences Prayer apps attracting huge investmentStartups using sound, light, and visuals to catalyze altered statesIntegrating ancient wisdom into modern consciousness-expanding techCredits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis,  Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Stanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. In this 3-part series, we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We start the series with Robert Malenka.Robert Malenka is a professor of psychiatry at Stanford University with over three decades of experience in preclinical neuroscience research. His primary focus is on the study of psychoactive drugs, including psychedelics, and their potential therapeutic applications. In addition to his academic role, Malenka is a founder and deputy director of the Wsai Neurosciences Institute at Stanford.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis,  Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Psychedelic Science 2023, Learning Man, MAPS Burn...whatever you want to call it...was a magical conference organized by MAPS.12k people made the pilgrimage to Denver to discuss psychedelic science, culture, business, art, spirituality, and more.Rick Doblin called this the "Psychedelic 20's" and this event felt like a watershed moment.Luckily, Greg brought his microphone and recorded his experience for a special episode of Business Trip.Guests include Zach Haigney, Myriam Barthes, Lauren Taus, Hamilton Morris, and many more…Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis,  Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

What does it take for a traditional VC to fund a psychedelic company? In our latest episode, Matias takes us behind the scenes of a panel discussion at the Psychedelic Therapeutics & Drug Development Conference in San Francisco, CA. Matias talks with VCs at firms with $100M+ fund sizes: Anne Dwane, a partner at Village Global, Amanda Way, principal at Jazz Venture Partners and Dana Watt PhD, principal at Breakout Ventures.In this episode, we discuss: (1) How VCs identify and evaluate a strong founding team, (2) Evaluating scientific, technical, and market risk, (3) The pros and cons of platforms vs. asset companies, (4) How to position a psychedelic company in the broader biotech ecosystem.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis,  Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

In our latest episode, Greg and Matias engage in an insightful discussion with Dr. Bryan Roth, the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine, and the founder of the Roth Lab.Dr. Roth’s lab is on the cutting edge of researching the interaction between brain cell receptors and compounds like LSD and psilocybin. Their findings have the potential to revolutionize the treatment of psychiatric disorders, potentially creating new forms of psychedelics that offer the therapeutic benefits without hallucinations or other side effects.In this episode, we discuss (1) the therapeutic effects of psychedelic and non-hallucinatory compounds, (2) the transition from animal model studies to human trials and (3) the journey of turning deep academic research into viable commercial entities.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis,  Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Dive into the intriguing world of PsyMed Ventures as the hosts share their journey in building a mental health-focused venture capital fund. Discover the challenges of fundraising over $15 million in the psychedelic and neurotechnology sectors while emphasizing community engagement. Learn how radical ideas are becoming mainstream and their profound impact on healthcare. The importance of strategic partnerships and cultivating trust as emerging managers is highlighted. Transforming mental health through innovative investments is at the forefront of this compelling conversation.

Josh Hardman, founder of Psychedelic Alpha, delves into the evolving psychedelic industry landscape, job opportunities, challenges in fundraising, therapy protocols, investor sentiment, and the significance of reciprocity and collaboration in the industry.

In this week’s special episode, Matias chats with Dr. Rachel Yehuda and Zach Haigney at Soho House in New York City. This is part 2 of a moderated panel recorded in front of a live audience, with part 1 released in June 2022. Dr. Yehuda has spent the last 30 years doing research on PTSD and trauma and is leading the MDMA-assisted therapy research at the US Veterans Affairs Medical Center and serves as Director at the Mental Health at the James J. Peters VA Medical Center. She is also the Director of the Center for Psychedelic Psychotherapy and Trauma Research at the Icahn School of Medicine at Mount Sinai Hospital and Professor of Psychiatry and Neuroscience. Zach Haigney writes the Trip Report by Beckley Waves, a newsletter about the science, policy, and business of psychedelics.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis,  Zack Frank, & Caitlin NerFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank